Moderna, Inc. (NASDAQ:MRNA) Shares Purchased by Douglas Lane & Associates LLC

Douglas Lane & Associates LLC raised its stake in Moderna, Inc. (NASDAQ:MRNA) by 62.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 773,804 shares of the company’s stock after buying an additional 298,715 shares during the period. Douglas Lane & Associates LLC owned approximately 0.20% of Moderna worth $32,175,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of the stock. State Street Corp raised its stake in Moderna by 12.1% during the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company’s stock valued at $1,125,899,000 after purchasing an additional 1,823,276 shares during the period. Geode Capital Management LLC grew its holdings in shares of Moderna by 2.6% during the third quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company’s stock valued at $470,670,000 after buying an additional 178,115 shares in the last quarter. Wellington Management Group LLP raised its position in Moderna by 21.0% during the third quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock valued at $349,166,000 after buying an additional 906,114 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Moderna by 0.5% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,890,812 shares of the company’s stock worth $260,023,000 after acquiring an additional 19,819 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its position in Moderna by 6.2% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 3,073,934 shares of the company’s stock worth $205,431,000 after acquiring an additional 178,939 shares during the period. 75.33% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have weighed in on MRNA. UBS Group dropped their price objective on shares of Moderna from $108.00 to $96.00 and set a “buy” rating on the stock in a research note on Wednesday. Wolfe Research started coverage on shares of Moderna in a research report on Friday, November 15th. They issued an “underperform” rating and a $40.00 price target on the stock. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $75.00 price objective on shares of Moderna in a report on Thursday, September 19th. Oppenheimer lowered Moderna from an “outperform” rating to a “market perform” rating in a research note on Friday, September 13th. Finally, Leerink Partners lowered their target price on Moderna from $60.00 to $48.00 and set an “underperform” rating on the stock in a report on Tuesday, September 17th. Four research analysts have rated the stock with a sell rating, twelve have issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Moderna currently has a consensus rating of “Hold” and an average target price of $78.83.

Moderna Price Performance

NASDAQ:MRNA traded down $3.95 on Wednesday, reaching $43.58. The stock had a trading volume of 9,826,371 shares, compared to its average volume of 10,336,079. Moderna, Inc. has a 1-year low of $35.80 and a 1-year high of $170.47. The stock has a fifty day moving average price of $43.22 and a 200-day moving average price of $70.88. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $16.77 billion, a P/E ratio of -7.49 and a beta of 1.60.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, November 7th. The company reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The firm had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. During the same quarter in the prior year, the firm earned ($1.39) EPS. The company’s revenue was up 3.8% on a year-over-year basis. Research analysts forecast that Moderna, Inc. will post -9.3 EPS for the current year.

Insider Activity

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the transaction, the insider now owns 19,717 shares of the company’s stock, valued at approximately $843,690.43. This represents a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have sold 2,664 shares of company stock valued at $115,210 over the last 90 days. 15.70% of the stock is owned by company insiders.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.